2021/04/12 ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) (Application No. 2019102895). Post author:alarpharm Post published:21 . 4 . 2021 Post category:Media releases You Might Also Like 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021 2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients 10 . 11 . 2021 2021/08/25 ALA-1000 Receive notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC), Application No. 2019/00890. 3 . 9 . 2021 2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021 2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients 10 . 11 . 2021
2021/08/25 ALA-1000 Receive notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC), Application No. 2019/00890. 3 . 9 . 2021
2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021
2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
